Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 101–200 of 999
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Srivastava, S., & Riddell, S. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701155 · Cited by 220
“Similar analysis of pre- and posttreatment biopsies and transcriptomic and epigenetic analysis of CD19 CAR T cells are being performed to identify mechanisms of resistance in the ∼50% of NHL patients that do not achieve a CR, and where CD19 loss is not the mechanism of escape (27, 28, 42, 140).”
ResultBoulch, M., Cazaux, M., Loe-Mie, Y., Thibaut, R., Corre, B., Lemaître, F., Grandjean, C. L., Garcia, Z., & Bousso, P. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd4344 · Cited by 218
Strati, P., Ahmed, S., Furqan, F., Fayad, L. E., Lee, H. J., Iyer, S. P., Nair, R., Nastoupil, L. J., Parmar, S., Rodriguez, M. A., et al. (2021) · Blood · doi:10.1182/blood.2020008865 · Cited by 218
Principles of adoptive T cell therapy in cancer
Met, Ö., Jensen, K. M., Chamberlain, C. A., Donia, M., & Svane, I. M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0703-z · Cited by 213
CAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214
Chimeric antigen receptor T-cell therapies for multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2017) · Blood · doi:10.1182/blood-2017-06-793869 · Cited by 212
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Yang, Y., Kohler, M. E., Chien, C. D., Sauter, C. T., Jacoby, E., Yan, C., Hu, Y., Wanhainen, K., Qin, H., & Fry, T. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1209 · Cited by 208
Chimeric antigen receptor T cell persistence and memory cell formation
McLellan, A. D., & Ali Hosseini Rad, S. M. (2019) · Immunology & Cell Biology · doi:10.1111/imcb.12254 · Cited by 206
“are lost, even in patients with complete responses, but is likely the result of the combination of the factors discussed above.(2,3) It is also possible that the sensitivity of polymerase Figure 1.”
BackgroundAnti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
Abramson, J. S., McGree, B., Noyes, S., Plummer, S., Wong, C., Chen, Y.-B., Palmer, E., Albertson, T., Ferry, J. A., & Arrillaga-Romany, I. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1704610 · Cited by 206
Gauthier, J., Bezerra, E. D., Hirayama, A. V., Fiorenza, S., Sheih, A., Chou, C. K., Kimble, E. L., Pender, B. S., Hawkins, R. M., Vakil, A., et al. (2021) · Blood · doi:10.1182/blood.2020006770 · Cited by 205
Self-citationGenetically engineered myeloid cells rebalance the core immune suppression program in metastasis
Kaczanowska, S., Beury, D. W., Gopalan, V., Tycko, A. K., Qin, H., Clements, M. E., Drake, J., Nwanze, C., Murgai, M., Rae, Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.048 · Cited by 203
Wang, D., Wang, J., Hu, G., Wang, W., Xiao, Y., Cai, H., Jiang, L., Meng, L., Yang, Y., Zhou, X., et al. (2021) · Blood · doi:10.1182/blood.2020008936 · Cited by 204
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
van der Lee, D. I., Reijmers, R. M., Honders, M. W., Hagedoorn, R. S., de Jong, R. C. M., Kester, M. G. D., van der Steen, D. M., de Ru, A. H., Kweekel, C., Bijen, H. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97482 · Cited by 200
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
Hunter, B. D., & Jacobson, C. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz017 · Cited by 193
Jain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M., Jacoby, E., Lazaryan, A., Jacobson, C. A., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2019.08.015 · Cited by 191
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M., Wang, M., Arnason, J., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., et al. (2024) · Blood · doi:10.1182/blood.2023020854 · Cited by 189
Drent, E., Poels, R., Ruiter, R., van de Donk, N. W. C. J., Zweegman, S., Yuan, H., de Bruijn, J., Sadelain, M., Lokhorst, H. M., Groen, R. W. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2559 · Cited by 190
Grigor, E. J. M., Fergusson, D., Kekre, N., Montroy, J., Atkins, H., Seftel, M. D., Daugaard, M., Presseau, J., Thavorn, K., Hutton, B., et al. (2019) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2019.01.005 · Cited by 188
Agarwal, S., Aznar, M. A., Rech, A. J., Good, C. R., Kuramitsu, S., Da, T., Gohil, M., Chen, L., Hong, S.-J. A., Ravikumar, P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.001 · Cited by 185
Harris, D. T., Hager, M. V., Smith, S. N., Cai, Q., Stone, J. D., Kruger, P., Lever, M., Dushek, O., Schmitt, T. M., Greenberg, P. D., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700236 · Cited by 182
Bollard, C. M., Tripic, T., Cruz, C. R., Dotti, G., Gottschalk, S., Torrano, V., Dakhova, O., Carrum, G., Ramos, C. A., Liu, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3179 · Cited by 181
CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
Li, J., Piskol, R., Ybarra, R., Chen, Y.-J. J., Li, J., Slaga, D., Hristopoulos, M., Clark, R., Modrusan, Z., Totpal, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8861 · Cited by 180
“Although IL-6 is often associated with CRS, increases in multiple other cytokines have been noted (24, 28, 30).”
BackgroundCytokine Release Syndrome: Current Perspectives
Murthy, H., Iqbal, M., Chavez, J. C., & Kharfan-Dabaja, M. A. (2019) · ImmunoTargets and Therapy · doi:10.2147/itt.s202015 · Cited by 178
“Clinical factors include disease burden and marrow involvement, lymphodepletion with fludarabine/cyclophosphamide conditioning, and higher CART infusion doses.(4,19,22,23) Other patient-specific factors such as pre-existent state of inflammation (baseline serum ferritin) and baseline endothelial activation (thrombocyt…”
BackgroundLickefett, B., Chu, L., Ortiz-Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D., Hudecek, M., Kremer, A., Markman, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 178
Kueberuwa, G., Kalaitsidou, M., Cheadle, E., Hawkins, R. E., & Gilham, D. E. (2018) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2017.12.003 · Cited by 179
Hay, K. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15644 · Cited by 176
CAR T Cell Toxicity: Current Management and Future Directions
Yáñez, L., Sánchez‐Escamilla, M., & Perales, M. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000186 · Cited by 175
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lee, L., Draper, B., Chaplin, N., Philip, B., Chin, M., Galas-Filipowicz, D., Onuoha, S., Thomas, S., Baldan, V., Bughda, R., et al. (2018) · Blood · doi:10.1182/blood-2017-05-781351 · Cited by 174
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Hirayama, A. V., Gauthier, J., Hay, K. A., Voutsinas, J. M., Wu, Q., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Riddell, S. R., et al. (2019) · Blood · doi:10.1182/blood.2019000905 · Cited by 173
CAR T-cell therapy in multiple myeloma: more room for improvement
Teoh, P. J., & Chng, W. J. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00469-5 · Cited by 170
Manufacturing chimeric antigen receptor T cells: issues and challenges
Roddie, C., O'Reilly, M., Dias Alves Pinto, J., Vispute, K., & Lowdell, M. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.11.009 · Cited by 168
Nerreter, T., Letschert, S., Götz, R., Doose, S., Danhof, S., Einsele, H., Sauer, M., & Hudecek, M. (2019) · Nature Communications · doi:10.1038/s41467-019-10948-w · Cited by 168
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
Quintarelli, C., Orlando, D., Boffa, I., Guercio, M., Polito, V. A., Petretto, A., Lavarello, C., Sinibaldi, M., Weber, G., Del Bufalo, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433518 · Cited by 163
Hill, J. A., Giralt, S., Torgerson, T. R., & Lazarus, H. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100596 · Cited by 163
“CAR-T cells are a ‘living’ drug, and as such, can survive in treated patients for years after infusion.[11,32-36] While this is likely beneficial for maintaining durable responses, it may result in persistent CD19+ B cell aplasia with possible risk for reduced humoral immunocompetence and infection.”
BackgroundMoghimi, B., Muthugounder, S., Jambon, S., Tibbetts, R., Hung, L., Bassiri, H., Hogarty, M. D., Barrett, D. M., Shimada, H., & Asgharzadeh, S. (2021) · Nature Communications · doi:10.1038/s41467-020-20785-x · Cited by 161
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156
“The depletion of TN cells likely reflected the influence of prior immune-stimulating and lymphodepleting therapies in the cancer patients analyzed (6, 33, 34).”
BackgroundSalter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abe2606 · Cited by 160
Immunotherapy for Brain Tumors
Sampson, J. H., Maus, M. V., & June, C. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8089 · Cited by 160
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
Salter, A. I., Pont, M. J., & Riddell, S. R. (2018) · Blood · doi:10.1182/blood-2018-01-785840 · Cited by 159
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti, A., Ponzo, M., Nicolette, C. A., Tcherepanova, I. Y., Biondi, A., & Magnani, C. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867013 · Cited by 180
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Subklewe, M. S., von Bergwelt‐Baildon, M., & Humpe, A. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000496870 · Cited by 177
Current challenges and emerging opportunities of CAR-T cell therapies
Abreu, T. R., Fonseca, N. A., Gonçalves, N., & Moreira, J. N. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.047 · Cited by 176
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
Sun, S., He, H., Yang, G., Zhang, Y., & Fu, Y. (2018) · Journal of Immunology Research · doi:10.1155/2018/2386187 · Cited by 183
“, PD-1 [95]) ensure the limited persistence of the redirected T cells; conversely, the regulation of affinity may be achieved via high-affinity TCR/CAR detection [96].”
Background4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Li, G., Boucher, J. C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L., Beatty, N., Abate-Daga, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121322 · Cited by 154
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 183
“The pathogenesis of Neurologic Adverse events (AE) is still unknown, in 2017, Gust et al. reported in 133 adults with refractory B-ALL, NHL, or CLL that followed by the endothelial activation the blood-brain barrier might be disrupted allowing high circulating cytokines to access the cerebrospinal fluid.”
BackgroundInfluentialCAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 169
Cao, Y., Lu, W., Sun, R., Jin, X. K., Cheng, L., He, X., Wang, L., Yuan, T., Lyu, C., & Zhao, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00767 · Cited by 158
“Multicenter clinical trials for relapsed or refractory DLBCL have showed encouraging preliminary data, with CR rates ranging from 33 to 57% (12, 13).”
BackgroundGreco, B., Malacarne, V., Girardi, F. D., Scotti, G. M., Manfredi, F., Angelino, E., Sirini, C., Camisa, B., Falcone, L., Moresco, M. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg3072 · Cited by 169
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
D’Agostino, M., & Raje, N. S. (2019) · Leukemia · doi:10.1038/s41375-019-0669-4 · Cited by 166
Sommer, C., Boldajipour, B., Kuo, T. C., Bentley, T., Sutton, J., Chen, A., Geng, T., Dong, H., Galetto, R., Valton, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.001 · Cited by 151
Engineered off-the-shelf therapeutic T cells resist host immune rejection
Mo, F., Watanabe, N., McKenna, M. K., Hicks, J. M., Srinivasan, M., Gomes‐Silva, D., Atilla, E., Smith, T. S., Atilla, P. A., Ma, R., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0601-5 · Cited by 166
Chimeric antigen receptor T cell therapy for autoimmune disease
Chung, J. B., Brudno, J. N., Borie, D. C., & Kochenderfer, J. N. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01035-3 · Cited by 181
Juluri, K. R., Wu, Q. V., Voutsinas, J. M., Hou, J., Hirayama, A. V. V., Mullane, E., Miles, N., Maloney, D. G., Turtle, C. J., Bar, M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2020004142 · Cited by 170
“Pre-LD platelets (310(9)/L), median (IQR) [range] 110 (48, 200) [9-339] 114 (86, 146) [7-434] 143 (80, 214) [9-448] 123 (64, 196) [7-448]”
Sun, D.-Y., Hu, Y.-J., Li, X., Peng, J., Dai, Z., & Wang, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113392 · Cited by 173
Ramachandran, I., Lowther, D. E., Dryer-Minnerly, R., Wang, R., Fayngerts, S., Nunez, D., Betts, G. J., Bath, N. M., Tipping, A. J., Melchiori, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0762-2 · Cited by 158
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Wei, J., Liu, Y., Wang, C., Zhang, Y., Tong, C., Dai, G., Wang, W., Rasko, J. E. J., Melenhorst, J. J., Qian, W., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00256-x · Cited by 150
“Although there are some supporting data, the main concern is that the dose reduction will impair the therapeutic benefits, which is particularly concerning in B-NHL.(51) Therefore, until clear evidence is provided, we do not recommend reducing the CAR T-cell dose to reduce the severity of CRS.”
BackgroundInfluentialRiegler, L. L., Jones, G. P., & Lee, D. W. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150524 · Cited by 158
“,12–20 Several attempts to develop a consistent and consensus-based grading system for CRS have occurred as CAR T-cell therapy has evolved.”
BackgroundHay, K. A., & Turtle, C. J. (2017) · Drugs · doi:10.1007/s40265-017-0690-8 · Cited by 141
“We recently reported treatment of 32 patients with a variety of B-NHL histologic types (11 de novo DLBCL, ten transformed DLBCL, five FL, and four MCL) [11].”
Toxicities of CD19 CAR‐T cell immunotherapy
Hirayama, A. V. V., & Turtle, C. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25445 · Cited by 152
“B cells, effective CD19 CAR-T cell therapy will be accompanied by B cell aplasia, which can be managed by the periodic administration of intravenous immunoglobulin (IVIG).(2,4,6,9,12,15,45)”
BackgroundEngineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 156
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Scarfò, I., Ormhøj, M., Frigault, M. J., Castaño, A. P., Lorrey, S., Bouffard, A. A., Scoyk, A. V., Rodig, S. J., Shay, A. J., Aster, J. C., et al. (2018) · Blood · doi:10.1182/blood-2018-04-842708 · Cited by 149
Cytokine release syndrome: grading, modeling, and new therapy
Liu, D., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0653-x · Cited by 145
Slaga, D., Ellerman, D. A., Lombana, T. N., Vij, R., Li, J., Hristopoulos, M. L., Clark, R., Johnston, J., Shelton, A., Mai, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat5775 · Cited by 145
Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
Mardiana, S., Solomon, B., Darcy, P. K., & Beavis, P. A. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2293 · Cited by 143
Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
Rubin, D. B., Jarrah, A. A., Li, K., LaRose, S. L., Monk, A. D., Ali, A. B., Spendley, L. N., Nikiforow, S., Jacobson, C. A., & Vaitkevicius, H. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2703 · Cited by 144
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
Roberts, Z. J., Better, M., Bot, A., Roberts, M. R., & Ribas, A. (2018) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1387905 · Cited by 136
Gene Therapy 2017: Progress and Future Directions
Keeler, A., ElMallah, M., & Flotte, T. (2017) · Clinical and Translational Science · doi:10.1111/cts.12466 · Cited by 133
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Xia, A., Wang, X., Lu, Y., Lu, X., & Sun, B. (2017) · Oncotarget · doi:10.18632/oncotarget.19361 · Cited by 140
“Objective regression was achieved in patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and other types of B cell lymphoma via application of CAR T cells which are redirected against CD19 [8, 11, 12, 23].”
BackgroundResultAnti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma
Abramson, J. S. (2019) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2019.08.003 · Cited by 135
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
Ruella, M., & Kenderian, S. S. (2017) · BioDrugs · doi:10.1007/s40259-017-0247-0 · Cited by 140
“Moreover, these T cells have demonstrated a potent anti-leukemic activity when used in an autologous setting against non-Hodgkin lymphoma [35].”
BackgroundInsights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
Gauthier, J., & Turtle, C. J. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.003 · Cited by 147
CAR-T efficacy: is conditioning the key?
Neelapu, S. S. (2019) · Blood · doi:10.1182/blood-2019-03-900928 · Cited by 144
Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
Jiang, H., Liu, L., Guo, T., Wu, Y., Ai, L., Deng, J., Dong, J. W., Mei, H., & Hu, Y. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03685-z · Cited by 141
Engineering interferons and interleukins for cancer immunotherapy
Holder, P. G., Lim, S. A., Huang, C., Sharma, P. A., Dagdas, Y. S., Bulutoglu, B., & Sockolosky, J. T. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114112 · Cited by 139
Castella, M., Boronat, A., Martín-Ibáñez, R., Rodríguez, V., Suñé, G., Caballero, M., Marzal, B., Pérez-Amill, L., Martín-Antonio, B., Castaño, J., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.010 · Cited by 126
Gene Therapy with the Sleeping Beauty Transposon System
Kebriaei, P., Izsvák, Z., Narayanavari, S. A., Singh, H., & Ivics, Z. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.008 · Cited by 142
Michels, K. R., Sheih, A., Hernández, S., Brandes, A., Parrilla, D., Irwin, B., Perez, A. M., Ting, H.-A., Nicolai, C. J., Gervascio, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006292 · Cited by 146
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
Lam, N., Trinklein, N. D., Buelow, B., Patterson, G. H., Ojha, N., & Kochenderfer, J. N. (2020) · Nature Communications · doi:10.1038/s41467-019-14119-9 · Cited by 131
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Titov, A., Petukhov, A., Staliarova, A., Motorin, D., Bulatov, E., Shuvalov, O. Y., Soond, S. M., Piacentini, M., Melino, G., Zaritskey, A. Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0918-x · Cited by 134
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Fabrizio, V. A., Boelens, J. J., Mauguen, A., Baggott, C., Prabhu, S., Egeler, E. L., Mavroukakis, S. A., Pacenta, H. L., Phillips, C. L., Rossoff, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006418 · Cited by 136
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
Hadiloo, K., Taremi, S., Heidari, M., & Esmaeilzadeh, A. (2023) · Biomarker Research · doi:10.1186/s40364-023-00537-x · Cited by 143
Smith, E. L., Staehr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.016 · Cited by 118
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Cohen, A. D., Raje, N. S., Fowler, J. A., Mezzi, K., Scott, E., & Dhodapkar, M. V. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2111 · Cited by 125
“Lymphodepletion has enhanced the clinical benefit of CAR T-cell therapy in hematologic malignancies (60, 61), suggesting that preconditioning is an important procedure for this therapeutic class.”
BackgroundImproving CAR T-Cell Persistence
Pietrobon, V., Todd, L. A., Goswami, A., Stefanson, O., Yang, Z., & Marincola, F. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910828 · Cited by 133
Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells
Maulana, T. I., Teufel, C., Cipriano, M., Roosz, J., Lazarevski, L., van den Hil, F. E., Scheller, L., Orlova, V. V., Koch, A., Hudecek, M., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.04.018 · Cited by 137
Seif, M., Kakoschke, T. K., Ebel, F., Bellet, M. M., Trinks, N., Renga, G., Pariano, M., Romani, L. R., Tappe, B., Espie, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1209 · Cited by 123
“Nevertheless, on the basis of our prior work showing the synergy between CD8+ and CD4+ CAR T cells in combating malignant diseases (48, 49) and the strong synergy between CD4+ Af-CAR T cells and macrophages in our in vitro assays, we would argue in favor of a defined composition Af-CAR product with both CD8+ and CD4+…”
BackgroundOei, V. Y. S., Kłopotowska, M., Graczyk‐Jarzynka, A., Hoel, H. J., Yang, W., Palacios, D., Almåsbak, H., Bajor, M., Clement, D., Brandt, L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0207 · Cited by 109
“Selective engineering of specific cell populations has also been tested clinically with promising results (10, 11).”
BackgroundCAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Rodriguez-Marquez, P., Calleja-Cervantes, M. E., Serrano, G., Oliver-Caldes, A., Palacios-Berraquero, M. L., Martin-Mallo, A., Calviño, C., Español-Rego, M., Ceballos, C., Lozano, T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo0514 · Cited by 109
Development of CAR T cells designed to improve antitumor efficacy and safety
Jaspers, J. E., & Brentjens, R. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.012 · Cited by 107
“…is dependent on many factors, including the costimulatory domain(s) (Zhao et al., 2015), tumor burden (Brentjens et al., 2011), lymphodepletion prior to CAR T cell therapy (Turtle et al., 2016) and stimulation of activation-induced T-cell inhibitory proteins, such as PD-1 (Cherkassky et al., 2016).”
BackgroundActivation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
Chen, P.-H., Lipschitz, M., Weirather, J. L., Jacobson, C., Armand, P., Wright, K., Hodi, F. S., Roberts, Z. J., Sievers, S. A., Rossi, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134612 · Cited by 107
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
Staflin, K., de Zafra, C. L. Z., Schutt, L., Clark, V., Zhong, F., Hristopoulos, M. L., Clark, R., Li, J., Mathieu, M. A., Chen, X., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133757 · Cited by 116
The Pharmacology of T Cell Therapies
Milone, M. C., & Bhoj, V. G. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.010 · Cited by 105
Sanber, K. S., Savani, B. N., & Jain, T. (2021) · British Journal of Haematology · doi:10.1111/bjh.17544 · Cited by 118
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
Chang, Z. L., & Chen, Y. Y. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.002 · Cited by 103
“sorting as well as in immunochemistry [4,5], rendering it a multipurpose addition to therapeutic CAR-T cells.”
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
Shadman, M. S., Gauthier, J., Hay, K. A., Voutsinas, J. M., Milano, F., Li, A., Hirayama, A. V. V., Sorror, M. L., Cherian, S., Chen, X., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000593 · Cited by 110
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
Brandt, L. J. B., Barnkob, M. B., Michaels, Y. S., Heiselberg, J., & Barington, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00326 · Cited by 102
Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor‐T Cells in Humans
Liu, C., Ayyar, V. S., Zheng, X., Chen, W., Zheng, S., Mody, H. R., Wang, W., Heald, D., Singh, A. P., & Cao, Y. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2040 · Cited by 110
CAR-T Cell Therapy: From the Shop to Cancer Therapy
Uscanga‐Palomeque, A. C., Chávez-Escamilla, A. K., Alvizo-Báez, C. A., Saavedra-Alonso, S., Terrazas-Armendáriz, L. D., Támez-Guerra, R., Rodríguez-Padilla, C., & Alcocer-González, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115688 · Cited by 129
“After this clinical trial some other trials started, with encouraging results [18,21,22].”
ResultState of the art in CAR T cell therapy for CD19+ B cell malignancies
Frigault, M. J., & Maus, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129208 · Cited by 114
“As cellular immune responses against the murine portions of the anti-CD19 scFv (FMC63) have been demonstrated (52), subsequent generations of CD19+ CAR T cells may utilize humanized versions of the anti-CD19 scFv.”
BackgroundJafarzadeh, L., Masoumi, E., Fallah-Mehrjardi, K., Mirzaei, H. R., & Hadjati, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00702 · Cited by 109
“The authors also found that in the patients treated with cyclophosphamide and Flu, pre-conditioning regimens comprised of Flu could improve persistence of CAR T cells and disease-free survival of patients compared to cyclophosphamide alone (72).”
Background
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.